The G101V mutation is a de novo acquisition mutation, in contrast to pretreatment samples [131], that diminishes the merging of VTX with BCL2 by 180-fold and leads to the outgrowth of blast cells in the presence of the drug in vitro in CLL patients [128]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.